Gastroesophageal Reflux Disease
📧 Sign up to get email alerts when something new happens for Gastroesophageal Reflux Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-07-28FDA Approved: PANTOPRAZOLE SODIUM — Supplemental Application (Eugia US LLC)
The FDA approved a supplemental application for pantoprazole sodium from Eugia US LLC. The action pertains to an already approved generic, t…
-
FDA approval · 2022-07-28FDA Approved: CURIST ACID RELIEF — Supplemental Application (Little Pharma, Inc.)
FDA granted a supplemental approval for Curist Acid Relief containing famotidine 20 mg from Little Pharma, Inc., updating the ANDA with the …
-
FDA approval · 2022-07-26FDA Approved: PANTOPRAZOLE SODIUM DELAYED-RELEASE — Original Application (Lifestar Pharma LLC)
FDA approved pantoprazole sodium delayed-release through an original application for Lifestar Pharma LLC.
-
CLINICAL_TRIALS trial_result · 2022-07-13Clinical Trial Update: Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease [Phase 2]
Phase 2 clinical trial evaluating safety and efficacy of JP-1366 in patients with erosive gastroesophageal reflux disease (GERD) has complet…
-
CLINICAL_TRIALS trial_result · 2022-07-05Clinical Trial Update: LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve Gastrectomy [NA]
Clinical trial update for the LINX Reflux Management System in GERD patients after laparoscopic sleeve gastrectomy; status completed and res…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-06-24FDA Approved: ESOMEPRAZOLE MAGNESIUM — Original Application (Rising Pharma Holdings, Inc.)
FDA approved the original ANDA for esomeprazole magnesium as a generic proton pump inhibitor manufactured by Rising Pharma Holdings, Inc.
-
FDA approval · 2022-06-16FDA Approved: DEXLANSOPRAZOLE — Supplemental Application (ENDO USA, Inc.)
The FDA approved a supplemental application for dexlansoprazole submitted by ENDO USA, Inc.
-
FDA approval · 2022-06-09FDA Approved: PANTOPRAZOLE SODIUM — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for pantoprazole sodium from Lannett Company, enabling the marketing of this generic proton pump inh…
-
FDA approval · 2022-06-09FDA Approved: PANTOPRAZOLE SODIUM — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for pantoprazole sodium from NorthStar Rx LLC, a generic pantoprazole product.
-
FDA approval · 2022-06-03FDA Approved: FAMOTIDINE — Original Application (Zydus Lifesciences Limited)
The FDA approved an original abbreviated new drug application (ANDA) for famotidine from Zydus Lifesciences Limited, making a generic versio…
-
FDA approval · 2022-05-19FDA Approved: PANTOPRAZOLE SODIUM I.V. — Original Application (Piramal Critical Care)
FDA approved Pantoprazole sodium for injection (IV) from Piramal Critical Care under an original application.
-
FDA approval · 2022-05-18FDA Approved: PANTOPRAZOLE SODIUM — Original Application (Novadoz Pharmaceuticals LLC)
The FDA approved Pantoprazole sodium from Novadoz Pharmaceuticals LLC under an Original Application (ANDA216171), adding a generic pantopraz…
-
FDA approval · 2022-05-18FDA Approved: PANTOPRAZOLE SODIUM — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' pantoprazole sodium as an original ANDA generic product. It is indicated for GERD-related conditions su…
-
FDA approval · 2022-05-03FDA Approved: DEXLANSOPRAZOLE — Supplemental Application (ENDO USA, Inc.)
The FDA approved a supplemental application for a generic Dexlansoprazole from ENDO USA, Inc., enabling market availability.
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Assessment on Effects of Tongjiang Granule in Treating Nonerosive Reflux Disease Overlapping Epigastric Pain Syndrome [Phase 1, Phase 2]
Clinical trial update evaluating Tongjiang Granule for nonerosive reflux disease overlapping epigastric pain syndrome, currently in Phase 1/…
-
FDA approval · 2022-03-04FDA Approved: ACIPHEX — Supplemental Application (Waylis Therapeutics LLC)
The FDA approved a supplemental application for ACIPHEX (rabeprazole sodium) by Waylis Therapeutics LLC. The snippet does not specify the ex…
-
FDA approval · 2022-03-04FDA Approved: PREVACID SOLUTAB — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approves a supplemental application for PREVACID SOLUTAB (lansoprazole) from Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2022-03-04FDA Approved: OMEPRAZOLE — Supplemental Application (Apotex Corp)
FDA approved a supplemental application for Omeprazole submitted by Apotex Corp.
-
FDA approval · 2022-03-04FDA Approved: DEXILANT — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Dexilant (dexlansoprazole) from Takeda Pharmaceuticals America, expanding or modifying its l…
-
FDA approval · 2022-03-04FDA Approved: OMEPRAZOLE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for omeprazole submitted by Zydus Lifesciences Limited. The exact scope of the supplement (such as l…
-
FDA approval · 2022-03-04FDA Approved: OMEPRAZOLE — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application for a generic omeprazole product from Lannett Company, Inc.
-
FDA approval · 2022-03-04FDA Approved: PROTONIX I.V. — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application for PROTONIX I.V. (pantoprazole sodium), adding an intravenous formulation under Wyeth/Pfizer to exp…
-
FDA approval · 2022-03-04FDA Approved: OMEPRAZOLE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved Glenmark's supplemental application for omeprazole, a generic proton pump inhibitor, expanding or updating its approval for…
-
FDA approval · 2022-03-04FDA Approved: OMEPRAZOLE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for Camber Pharmaceuticals' Omeprazole, a generic proton pump inhibitor, under the ANDA process.
-
FDA label_change · 2022-03-04FDA Approved: NEXIUM — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for Nexium (esomeprazole magnesium) from AstraZeneca Pharmaceuticals LP.